Bangying F Su

20100068259, Mar 18, 2010

May 29, 2009

12/474904

Annette Tobia - Wyndmoor PA, US
Marcy Alice - Doylestown PA, US
Bangying Su - Elkins Park PA, US
Takeshi Niwa - Osaka, JP

A61K 9/127
A61K 35/56
A61K 36/00
A61K 38/16
A61K 36/73
A61K 36/87
A61P 17/00
A61K 36/31
A61K 35/12
A61K 36/8962
A61K 36/42
A61K 36/736
A61K 36/45
A61K 36/534
A61K 36/16
A61K 36/82
A61K 36/258
A23L 2/84
A23F 3/20

424450, 424547, 424769, 514 12, 424765, 424725, 424766, 424776, 424755, 424520, 424754, 424758, 424735, 424732, 424747, 424752, 424729, 424728, 424773, 424 59, 426 10

Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed.

20100297046, Nov 25, 2010

Mar 30, 2007

12/294182

Michael Schwartz - Palmyra NJ, US
Francis Kappler - Philadelphia PA, US
Bangying Su - Elkins Park PA, US

DYNAMIS THERAPEUTICS, INC. - Jenkintown PA

A61K 8/60
A61K 31/7036
A61K 31/517
A61K 8/49
A61K 31/56
A61K 31/573
A61K 31/7048
A61K 31/519
A61K 31/5415
A61K 31/497
C07D 491/22
A61K 31/44
A61K 31/47
A61P 17/00
A61P 17/06
A61P 17/08
A61P 35/00
A61P 29/00
A61P 43/00
A61P 37/08
A61P 9/10
A61P 19/06
A61P 19/02
A61P 25/28
A61P 25/06

424 60, 514 42, 514268, 514170, 514 29, 514249, 5142265, 51425401, 514257, 514344, 514314

The invention relates to compounds and methods for inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin, by way of fructosamine-3-kinase inhibition, thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.

20120231071, Sep 13, 2012

May 24, 2012

13/479419

Annette Tobia - Wyndmoor PA, US
Marcy Alice - Doylestown PA, US
Bangying Su - Elkins Park PA, US
Takashi Niwa - Osaka, JP

A61K 36/185
A61K 9/127
A61K 35/56
A61K 38/39
A61K 36/49
A61K 36/31
A61K 36/48
A61K 36/738
A61K 36/87
A61K 36/77
A61K 36/82
A61K 36/258
A61K 36/42
A61K 36/736
A61K 36/73
A61K 36/534
A61K 36/8962
A61K 36/81
A61K 36/899
A61K 8/97
A61K 47/46
A61K 47/18
A61K 47/42
A61K 8/55
A61K 8/44
A61K 8/65
A61P 17/00
A61Q 19/00
A23L 3/3454
A61Q 17/04

424450, 424 59, 424547, 514 172, 424769, 424755, 424757, 424725, 424765, 424766, 424729, 424728, 424758, 424747, 424754, 424750, 514783, 514784, 514773, 514772, 426321

Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed.

20130266638, Oct 10, 2013

Jun 3, 2013

13/908248

Alice Marcy - Doylestown PA, US
Bangying Su - Elkins Park PA, US
Takeshi Niwa - Osaka, JP

A61K 8/98
A61K 8/97
A61Q 19/08

424450, 424520, 514 172, 424765, 424725, 424757, 424758, 424754, 424766, 424735, 424747, 424752, 424729, 424773, 424732, 424748, 424745

Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed.

60049588, Dec 21, 1999

Feb 5, 1997

8/794433

Truman R. Brown - Laverock PA
Francis Kappler - Philadelphia PA
Benjamin Szwergold - Philadelphia PA
Sundeep Lal - Lansdale PA
Bangying Su - Philadelphia PA

Fox Chase Cancer Center - Philadelphia PA

A61K 31535
A61K 3119
A61K 3113
A61K 31045

5142388

The present invention is based on the discovery of a metabolic pathway in which a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction. Fructose-lysine-3-phosphate (FL3P) is then broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a cause of diabetic complications. Disclosed is a class of compounds which inhibit the action of FL3P kinase in the above-mentioned pathway. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications, as well as methods for assessing a diabetic's risk of developing complications and for determining the efficacy of the disclosed inhibitor therapy by measuring the ratio of 3DG to 3DF in a biological sample following an oral dose of a fructose-lysine-containing food product.

20160331798, Nov 17, 2016

Jul 25, 2016

15/218347

- Jenkintown PA, US
Alice Marcy - Doylestown PA, US
Bangying Su - Elkins Park PA, US
Takeshi Niwa - Osaka, JP

A61K 36/87
A61K 8/97
A61K 8/98
A61K 35/618
A61K 38/39
A61K 8/65
A61K 36/738
A61K 36/31
A61K 36/48
A61K 36/185
A61K 36/24
A61K 36/74
A61K 36/77
A61K 36/81
A61K 36/28
A61K 36/23
A61K 36/42
A61K 36/8962
A61K 36/82
A61K 31/722
A61K 31/375
A61K 31/198
A61K 31/51
A61K 31/197
A61K 31/4172
A61K 31/675
A61K 31/4415
A61K 31/133
A61K 31/7008
A61K 31/164
A61K 31/195
A61Q 19/08

Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed.